Phase I evaluation of CycloSam ® (Sm‐153‐DOTMP) bone seeking radiopharmaceutical in dogs with spontaneous appendicular osteosarcoma
Veterinary Radiology & Ultrasound · 2023-09 · 64 (5) · 982-991
DOI: 10.1111/vru.13274 ↗Kurz gefasst
Fachartikel in der Zeitschrift Veterinary Radiology & Ultrasound, online erschienen am 10.07.2023. Verfasst von Kim A Selting und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, Missouri, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Bone Neoplasms, Dog Diseases, Osteosarcoma. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH National Cancer Institute.
Abstract (Originalsprache)
153 Sm‐DOTMP (CycloSam ® ) is a newly‐patented radiopharmaceutical for bone tumor treatment. DOTMP (1,4,7,10‐tetraazacyclododecane‐1,4,7,10‐tetramethylene‐phosphonate) is a macrocyclic chelating agent with superior binding properties to 153 Sm when compared with EDTMP (Quadramet™, used for palliative treatment of bone cancer). CycloSam ® was administered at 1 mCi/kg (37 MBq/kg) in a prospective pilot study to seven dogs with bone cancer resulting in no myelosuppression. Then, 13 dogs were enrolled in a prospective clinical trial study using traditional 3+3 dose escalation and starting at 1.5 mCi/kg. Baseline evaluation included hematologic and biochemical testing, diagnosis confirmation, thoracic and limb radiographs, technetium‐99 m‐HDP bone scintigraphy, and 18 F‐FDG PET scan (SUVmax). Toxicity (primary endpoint) was assessed through weekly blood counts and adverse events. Dogs received 1.5 mCi/kg (n = 4), 1.75 mCi/kg (n = 6), and 2 mCi/kg (n = 3) of 153 Sm‐DOTMP. Dose‐limiting neutropenia and thrombocytopenia were seen at 2 mCi/kg. No dose‐limiting nonhematologic toxicities occurred. Efficacy (secondary endpoint) was assessed by objective lameness measurement (body‐mounted inertial sensors), owner quality‐of‐life (QoL) questionnaire, and repeat PET scan. Objective lameness measurement improved in four dogs (53%–60% decrease) was equivocal in three dogs, and worsened in four dogs (66%–115% increase); two dogs were not evaluable. Repeat 18 F‐FDG PET scan results varied and change in lameness did not consistently correlate with SUVmax changes. QoL score worsened (n = 5) or was improved/stable (n = 7). Carboplatin chemotherapy (300 mg/m2 IV every 3 weeks ×4) started 4 weeks after 153 Sm‐DOTMP injection. No dog died of chemotherapy‐related complications. All dogs completed study monitoring. The recommended dose for CycloSam ® in dogs is 1.75 mCi/kg, which resulted in some pain control with minimal toxicity and was safely combined with chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, Missouri, USA.
- IsoTherapeutics Group LLC, Angleton, Texas, USA.
- Department of Imaging Physics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
- Department of Medicine, Division of Internal Medicine, University of Missouri, Columbia, Missouri, USA.
ORCID-Profile: Kim A Selting, Jim C Lattimer, Charles Maitz
Förderung
- NIH National Cancer Institute
Zitieren
APA
Selting, K. A., Simon, J., Lattimer, J. C., Ketring, A., Axiak-Bechtel, S., Frank, K., Wendt, R. E., Bryan, J. N., Tate, D., Maitz, C., Lunceford, J., Donnelly, L., Keegan, K., & Henry, C. J. (2023). Phase I evaluation of CycloSam ® (Sm‐153‐DOTMP) bone seeking radiopharmaceutical in dogs with spontaneous appendicular osteosarcoma. Veterinary Radiology & Ultrasound, 64(5), 982-991. https://doi.org/10.1111/vru.13274
Vancouver
Selting KA, Simon J, Lattimer JC, Ketring A, Axiak-Bechtel S, Frank K, et al. Phase I evaluation of CycloSam ® (Sm‐153‐DOTMP) bone seeking radiopharmaceutical in dogs with spontaneous appendicular osteosarcoma. Veterinary Radiology & Ultrasound. 2023;64(5):982-991. doi:10.1111/vru.13274
BibTeX
@article{Selting2023,
author = {Selting, Kim A and Simon, Jaime and Lattimer, Jim C and Ketring, Alan and Axiak-Bechtel, Sandra and Frank, Keith and Wendt, Richard E and Bryan, Jeffrey N and Tate, Deborah and Maitz, Charles and Lunceford, Joni and Donnelly, Lindsay and Keegan, Kevin and Henry, Carolyn J},
title = {Phase I evaluation of CycloSam ® (Sm‐153‐DOTMP) bone seeking radiopharmaceutical in dogs with spontaneous appendicular osteosarcoma},
journal = {Veterinary Radiology & Ultrasound},
year = {2023},
volume = {64},
number = {5},
pages = {982--991},
doi = {10.1111/vru.13274}
}
EUVIMED